ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2025
The Analgesic Effect of Two Different Extended-Release Meloxicam Formulations for Attenuation of Hypersensitivity in Rats (Rattus norvegicus).
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) frequently administered every 24 hours to control mild to moderate pain in rodents. Extended-release meloxicam offers a refinement of less frequent dosing and an extended therapeutic window compared with the standard daily-dosed meloxicam formulation. The aim of this study was to compare the analgesic efficacy of 2 different extended-release meloxicam formulations to a standard meloxicam formulation in a rat incisional pain model. Adult Long-Evans rats (n = 33) were randomly assigned into one of 4 treatment groups (n = 8-9 per group): (1) saline (0.9% NaCl, 5 mL/kg, SC, once); (2) meloxicam (Melox; 2 mg/kg, SC, every 24 hours); (3) meloxicam extended-release polymer (Melox-ER; 4 mg/kg, SC, once); or (4) meloxicam extended-release suspension (Melox-XR; 4 mg/kg, SC, once). Under isoflurane anesthesia, a 1-cm longitudinal skin incision was made on the plantar hind paw 5 minutes after drug administration. Mechanical and thermal hypersensitivity assessments were performed one day before surgery (-24 hour), 4 hours after surgery (4 hour), and 3 consecutive days following surgery (24, 48, and 72 hours). Mechanical (4-48 hours) and thermal (4-72 hours) hypersensitivity were observed in the saline group. Melox-ER did not attenuate mechanical or thermal hypersensitivity at any time point. Melox and Melox-XR attenuated mechanical hypersensitivity at the 48-hour time point. No abnormal clinical signs were noted, but injection site reactions were noted in the Melox, Melox-ER, and Melox-XR groups. Further research is needed to evaluate rat meloxicam analgesic dosages for incisional pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.